Zhejiang Ausun Pharmaceutical Co Ltd, based in China, is a pharmaceutical company that stands out with its certifications from FDA and EDQM.
They are recognized for Accelerating Development of APIs & Chemical Intermediates through innovation.
One of their notable products is FEBUXOSTAT HEMIHYDRATE, with a corresponding US DMF Number 29716.
Remarkably, this DMF maintains an Active status since its submission on September 22, 2015, highlighting commitment to regulatory compliance.
Their GDUFA DMF Review was successfully complete, with a review date of August 01, 2017, and payment made on September 21, 2015, indicating their dedication to facilitating drug approvals, Categorized as Type II